The success of the monoclonal antibody tocilizumab targeting IL-6 in palmoplantar pustular psoriasis and psoriatic arthritis [64,65] has been overshadowed by the exacerbation of psoriasis in some of the treated patients [66]. The gene discussed is IL6; the disease is psoriasis.